# Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Study · id `cardio:ct-nct01743001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01743001](<https://clinicaltrials.gov/study/NCT01743001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01743001

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.

## Technical summary

Registry record NCT01743001. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-21 (actual); primary completion 2016-12-01 (actual). Results posted on 2018-01-30.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 226 participants (enrolled count; ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Started: 2013-05-21 (actual) (ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Primary completion: 2016-12-01 (actual) (ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Completion: 2016-12-01 (actual) (ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Results first posted: 2018-01-30 (ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Countries: United States; Austria; Bulgaria; Chile; China; France; Germany; Greece; Israel; Malaysia; Mexico; Philippines; Poland; Portugal; Romania; Russia; Serbia; Spain; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT01743001, source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01743001-2018-02-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
- Acronym: MAESTRO
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Macitentan 10 mg
- Intervention (Drug): Placebo
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evaluation of Macitentan in Patients With Eisenmenger Syndrome (`cardio:pubmed-30586694`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 99ba44afa3e59b426c4c166fee04b8d04f8ff3b0e45c01efd72e7ac6c0832524
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
